Exploring the Link Between LSD and Anxiety
Mercola, November 15, 2025
LSD shows promise for anxiety treatment. A Phase 2b clinical trial found that 100 micrograms of MM120 (pharmaceutical LSD) reduced anxiety significantly with lasting effects.
Psychedelics might help terminal patients find peace
The Conversation, November 15, 2025
For many, the hardest part of dying isn’t physical pain but the fear, anxiety and sense of meaninglessness that often accompany it. This is where psychedelic therapy may offer support.
Psychedelics funding given green light by DVA
Medical Republic, November 10, 2025
The Department of Veteran Affairs can now fund psychedelic-assisted psychotherapy (PAP) using MDMA or psilocybin for eligible Veteran Card holders. With this move, Australia is now the global leader in this area of medicine.
FDA Grants Breakthrough Therapy Designation to Beckley and Atai’s 5-MeO-DMT Program
Psychedelic Health, October 22, 2025
Last week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to 5-MeO-DMT, also known as toad venom, in a significant advancement for psychedelic medicine.
Depression patients ‘amazingly better’ after magic mushie therapy
Herald Sun, October 13, 2025
Researchers hope an Aussie-first magic mushroom pilot — which returned “promising” results for depression patients — could be a game changer for those who get no relief from current treatments.
Lasting relief from depression after magic-mushroom treatment – new study
The Conversation, September 20, 2025
Two-thirds of people who underwent psilocybin-assisted therapy remained free from depression five years later, according to recent research that offers the first long-term glimpse into the lasting power of psychedelic treatment. This is in stark contrast to traditional antidepressants.
MDMA should be licensed for veterans with PTSD
The Spectator, September 20, 2025
The documentary Dead Dog on the Left chronicles the journey through the no-man’s land of complex PTSD, which in turn triggered alcoholism and suicidal thoughts, to an eventual recovery, aided by MDMA-led psychotherapy.
Depression remission endures 5 years after psilocybin trial
Osu.Edu, September 10, 2025
Two-thirds of clinical trial participants treated with psilocybin-assisted therapy for major depressive disorder were in complete remission from their depression five years later, a new study has found.
Tryptamine secures landmark EEG biomarker deal to advance precision psychiatry
The Australian, August 22, 2025
Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin Carhart-Harris and Professor Pedro Mediano to develop a first-of-its-kind electroencephalogram (EEG) based brain entropy biomarker.
Australian-first psychedelic-assisted therapy trial for terminally ill patients shows improved quality of life
ABC News, August 20, 2025
A small psychedelic-assisted therapy trial shows rapid and sustained reductions in depression and anxiety, while improving overall quality of life.
Oregon sees 1,500 users access psilocybin services in four months
Koin, July 29, 2025
More than 1,500 people accessed psilocybin services between January and April, according to data from the Oregon Health Authority.
Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
British Journal of Pharmacology, July 28, 2025
A major peer-reviewed review published in the British Journal of Pharmacology has found that psychedelic-assisted therapies may offer powerful anti-inflammatory benefits alongside their well-documented mental health applications. Researchers found that compounds including psilocybin can reduce pro-inflammatory cytokines, with effects lasting up to 7 days from a single dose. The review also introduces a new class of compounds that retain therapeutic potential without evoking psychedelic experiences, opening new avenues for treatment across both mental health and inflammatory disease.
Psychedelic Drug May Slow Aging
Newsweek, July 10, 2025
Could psilocybin hold the key to slowing down aging? New research from Georgia’s Emory University suggests they just might.
New Zealand approves psilocybin to treat depression
NZ Ministry of Health, June 19, 2025
Medsafe has given a New Zealand psychiatrist approval to prescribe medicinal psilocybin for treating treatment-resistant depression. This is the first time psilocybin will be prescribed outside of a research setting in New Zealand, and will give people with this severe condition more options.
MDMA to treat PTSD? Medibank says Y-E-S
The Australian, June 18, 2025
Emyria (ASX: EMD) has secured the support of Medibank Private (ASX: MPL) to fund the company’s post-traumatic stress disorder (PTSD) care program it has developed through the Perth Clinic. The agreement is the first for a major private health insurer funding a psychotherapy-led PTSD program in Australia, allowing Emyria to offer patients its Empax PTSD treatment without any out-of-pocket expenses.
New Zealand Gives Nod To ‘Magic Mushrooms’ For Medicinal Purpose
MSN, June 18, 2025
New Zealand on Wednesday approved the medicinal use of psilocybin. Deputy Prime Minister David Seymour said rules had been relaxed so psilocybin could be used to treat certain types of depression.
Czech Republic opens door to psychedelic therapies for mental health conditions
Parea, June 5, 2025
In a recent vote, the Czech Parliament passed legislation that paves the way for qualified psychiatrists to administer psilocybin in accredited medical facilities as part of assisted psychotherapy.
Psilocybin and IBS treatment: First psychedelic study in gastroenterology
Open Access Government, June 5, 2025
In a groundbreaking first, psilocybin is entering gastroenterology.
Emyria reports promising PTSD recovery data 6 months after treatment
Next Investors, May 28, 2025
63% of patients no longer met the PTSD criteria, with symptoms dropping 55.5% on average.
Psychedelic ‘wonder drug’ of the ‘60s can improve Parkinson’s symptoms for weeks
NY Post, May 1, 2025
Psilocybin — the psychedelic compound that gave “magic mushrooms” their trippy reputation in the 1960s — is now showing serious promise for improving mood and motor function in people with Parkinson’s disease, according to a groundbreaking recent study.